{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:33:30Z","timestamp":1793705610348,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GSK study identifier 207685"],"award-info":[{"award-number":["GSK study identifier 207685"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Estimate the incidence of herpes zoster (HZ), its complications and healthcare utilization rates in adults (\u2265 18-years-old) with a wide range of immunocompromised (IC) conditions compared to IC-free cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A population-based retrospective study using the Valencia healthcare Integrated Databases (VID) (2009\u20132014). HZ and IC were defined using ICD-9 codes in primary care (PC) and hospitalization registers. Incidence rates (IR), risk of HZ, HZ-recurrence, HZ-complications and healthcare utilization rates were estimated in the IC-cohort compared to IC-free.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study population consisted of 4,382,590 subjects, of which 578,873 were IC (13%). IR (in 1000 persons-year) of HZ overall, in IC and in IC-free cohort was 5.02, 9.15 and 4.65, respectively. IR of HZ increased with age in both cohorts and it was higher for all IC conditions studied, reaching up to twelvefold in subjects with stem cell transplantation. IC subjects had 51% higher risk of developing HZ, 25% higher HZ-recurrence and the risk of HZ-complications was 2.37 times higher than in IC-free. HZ-related healthcare utilization was higher in the IC-cohort than in IC-free (number of hospitalizations 2.93 times greater, hospital stays 12% longer, 66% more HZ-specialist visits, 2% more PC visits, sick leaves 18% longer and 20% higher antiviral dispensation).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients suffering from all the IC conditions studied are at higher risk of developing HZ, HZ-recurrence and post-herpetic complications, which implies a substantial morbidity and a high consumption of resources. These results should be considered for vaccine policy implementation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-05648-6","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T17:05:20Z","timestamp":1606755920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009\u20132014"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-4905","authenticated-orcid":false,"given":"Cintia","family":"Mu\u00f1oz-Quiles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"L\u00f3pez-Lacort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edez-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Orrico-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"issue":"2","key":"5648_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jinf.2018.04.004","volume":"77","author":"C Munoz-Quiles","year":"2018","unstructured":"Munoz-Quiles C, Lopez-Lacort M, Orrico-Sanchez A, Diez-Domingo J. Impact of postherpetic neuralgia: a six year population-based analysis on people aged 50 years or older. J Infect. 2018;77(2):131\u20136.","journal-title":"J Infect"},{"key":"5648_CR2","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1086\/522123","volume":"197","author":"AM Arvin","year":"2008","unstructured":"Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197:S58\u201360..","journal-title":"J Infect Dis"},{"issue":"2","key":"5648_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","volume":"42","author":"SY Chen","year":"2014","unstructured":"Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325\u201334.","journal-title":"Infection."},{"key":"5648_CR4","first-page":"g2911","volume":"348","author":"HJ Forbes","year":"2014","unstructured":"Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ (Clinical research ed). 2014;348:g2911.","journal-title":"BMJ (Clinical research ed)"},{"issue":"3","key":"5648_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jinf.2017.06.010","volume":"75","author":"C Schroeder","year":"2017","unstructured":"Schroeder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75(3):207\u201315.","journal-title":"J Infect"},{"issue":"16","key":"5648_CR6","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2010;182(16):1731\u20136.","journal-title":"CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne"},{"key":"5648_CR7","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1186\/s12889-015-1514-y","volume":"15","author":"A Gater","year":"2015","unstructured":"Gater A, Uhart M, McCool R, Preaud E. The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review. BMC public health. 2015;15:1514.","journal-title":"BMC public health"},{"issue":"16","key":"5648_CR8","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","volume":"371","author":"RW Johnson","year":"2014","unstructured":"Johnson RW, Rice ASC. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"5648_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","volume":"87","author":"HJ Forbes","year":"2016","unstructured":"Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology. 2016;87(1):94\u2013102.","journal-title":"Neurology."},{"key":"5648_CR10","doi-asserted-by":"publisher","first-page":"CD006866","DOI":"10.1002\/14651858.CD006866.pub3","volume":"2","author":"N Chen","year":"2014","unstructured":"Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014 Feb 6;2:CD006866. https:\/\/doi.org\/10.1002\/14651858.CD006866.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"5648_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin M-J, Bijl M, Franco E, Gaillat J, Clara JG, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic Advances Vaccines. 2015;3(4):109\u201320.","journal-title":"Therapeutic Advances Vaccines"},{"issue":"22","key":"5648_CR12","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384.","journal-title":"N Engl J Med"},{"issue":"RR-5","key":"5648_CR13","first-page":"1","volume":"57","author":"R Harpaz","year":"2008","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices Centers for D, Control and P. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations Rep. 2008;57(RR-5):1\u201330 quiz CE2\u20134. PMID: 18528318.","journal-title":"MMWR Recommendations Rep"},{"issue":"6","key":"5648_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/ciw854","volume":"64","author":"HS Izurieta","year":"2017","unstructured":"Izurieta HS, Wernecke M, Kelman J, Wong S, Forshee R, Pratt D, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older. Clin Infect Dis. 2017;64(6):785\u201393.","journal-title":"Clin Infect Dis"},{"key":"5648_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","volume":"167","author":"M Mareque","year":"2019","unstructured":"Mareque M, Oyaguez I, Morano R, Casado MA. Systematic review of the evidence on the epidemiology of herpes zoster: incidence inthegeneral population and specific subpopulationsin Spain. Public Health. 2019;167:136\u201346.","journal-title":"Public Health"},{"issue":"1","key":"5648_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12879-018-3121-x","volume":"18","author":"C Mu\u00f1oz-Quiles","year":"2018","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, D\u00edez-Domingo J. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009-2014. BMC Infect Dis. 2018;18(1):203.","journal-title":"BMC Infect Dis"},{"key":"5648_CR17","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, Ampudia-Blasco FJ, D\u00edez-Domingo J. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009-2014. Hum Vaccin Immunother. 2017;;13(11):2606-2611. https:\/\/doi.org\/10.1080\/21645515.2017.1368600.","DOI":"10.1080\/21645515.2017.1368600"},{"issue":"1","key":"5648_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/j.pain.0000000000000307","volume":"157","author":"HJ Forbes","year":"2016","unstructured":"Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30\u201354.","journal-title":"Pain."},{"key":"5648_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.puhe.2016.10.013","volume":"142","author":"L Varghese","year":"2017","unstructured":"Varghese L, Curran D, Bunge E, Vroling H, van Kessel F, Guignard A, et al. Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK. Public Health. 2017;142:46\u20139.","journal-title":"Public Health"},{"issue":"22","key":"5648_CR20","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an Adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396.","journal-title":"N Engl J Med"},{"issue":"7","key":"5648_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","volume":"17","author":"N Lecrenier","year":"2018","unstructured":"Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher J-P, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Review of Vaccines. 2018;17(7):619\u201334.","journal-title":"Expert Review of Vaccines"},{"key":"5648_CR22","doi-asserted-by":"publisher","unstructured":"Bastidas A, de la Serna J, El Idrissi M. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. Jama-J Am Med Assoc (vol 322, pg 123, 2019). doi: https:\/\/doi.org\/10.1001\/jama.2019.9053.","DOI":"10.1001\/jama.2019.9053"},{"key":"5648_CR23","doi-asserted-by":"publisher","unstructured":"Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301\u201312. https:\/\/doi.org\/10.1002\/cncr.31909.","DOI":"10.1002\/cncr.31909"},{"issue":"2","key":"5648_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/cid\/ciz177","volume":"70","author":"P Vink","year":"2020","unstructured":"Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim S-J, Kim S-I, Zaltzman J, et al. Immunogenicity and safety of the Adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3. Randomized Clin Trial Clin Infect Dis. 2020;70(2):181\u201390. https:\/\/doi.org\/10.1093\/cid\/ciz177.","journal-title":"Randomized Clin Trial Clin Infect Dis"},{"key":"5648_CR25","doi-asserted-by":"publisher","unstructured":"Satyam VR, Li P-H, Reich J, Qazi T, Noronha A, Wasan SK, et al. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease. Digestive Diseases Sci. 2020;65(10):2986\u201391. https:\/\/doi.org\/10.1007\/s10620-019-06016-4.","DOI":"10.1007\/s10620-019-06016-4"},{"key":"5648_CR26","doi-asserted-by":"publisher","unstructured":"Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000\u20132012. Bmj Open. 2018;8(6):e020528. https:\/\/doi.org\/10.1136\/bmjopen-2017-020528.","DOI":"10.1136\/bmjopen-2017-020528"},{"key":"5648_CR27","doi-asserted-by":"publisher","unstructured":"Imafuku S, Matsuki T, Mizukami A, Goto Y, de Souza S, Jegou C, et al. Burden of herpes zoster in the Japanese population with Immunocompromised\/chronic disease conditions: results from a cohort study claims database from 2005-2014. Dermatol Ther. 2018. https:\/\/doi.org\/10.1007\/s13555-018-0268-8.","DOI":"10.1007\/s13555-018-0268-8"},{"key":"5648_CR28","doi-asserted-by":"publisher","unstructured":"Garcia-Sempere A, Orrico-Sanchez A, Munoz-Quiles C, Hurtado I, Peiro S, Sanfelix-Gimeno G, et al. Data resource profile: the Valencia health system integrated database (VID). Int J Epidemiol. 2020;49(3):740-41e. https:\/\/doi.org\/10.1093\/ije\/dyz266.","DOI":"10.1093\/ije\/dyz266"},{"issue":"48","key":"5648_CR29","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1016\/j.vaccine.2016.10.032","volume":"34","author":"M Lopez-Lacort","year":"2016","unstructured":"Lopez-Lacort M, Collado S, Diez-Gandia A, Diez-Domingo J. Rotavirus, vaccine failure or diagnostic error? Vaccine. 2016;34(48):5912\u20135.","journal-title":"Vaccine."},{"key":"5648_CR30","doi-asserted-by":"publisher","unstructured":"Perez-Vilar S, Diez-Domingo J, Lopez-Lacort M, Martinez-Ubeda S, Martinez-Beneito MA. Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia region. Spain Bmc Infectious Diseases. 2015;;65(5):840-850. https:\/\/doi.org\/10.1093\/cid\/cix369.","DOI":"10.1093\/cid\/cix369"},{"issue":"4","key":"5648_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","volume":"36","author":"S Garcia","year":"2016","unstructured":"Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients a systematic review. J Clin Psychopharmacol. 2016;36(4):355\u201371.","journal-title":"J Clin Psychopharmacol"},{"key":"5648_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/1471-2334-13-463","volume":"13","author":"N Morant-Talamante","year":"2013","unstructured":"Morant-Talamante N, Diez-Domingo J, Martinez-Ubeda S, Puig-Barbera J, Aleman-Sanchez S, Perez-Breva L. Herpes zoster surveillance using electronic databases in the Valencian community (Spain). BMC Infect Dis. 2013;13:463.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"5648_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s15010-014-0645-x","volume":"42","author":"AP Guignard","year":"2014","unstructured":"Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997-2006. Infection. 2014;42(4):729\u201335.","journal-title":"Infection."},{"issue":"2","key":"5648_CR34","doi-asserted-by":"publisher","first-page":"ofu049","DOI":"10.1093\/ofid\/ofu049","volume":"1","author":"JA Suaya","year":"2014","unstructured":"Suaya JA, Chen S-Y, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis. 2014;1(2):ofu049.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"5648_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/INF.0000000000001040","volume":"35","author":"S Weinmann","year":"2016","unstructured":"Weinmann S, Vandermeer M, Roberts M, Mullooly J, Chun C. Positive predictive value of ICD-9 code for herpes zoster among children during the varicella vaccine era. Pediatr Infect Dis J. 2016;35(4):459\u201360.","journal-title":"Pediatr Infect Dis J"},{"key":"5648_CR36","doi-asserted-by":"publisher","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. Bmj Open. 2014;4(6):e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","DOI":"10.1136\/bmjopen-2014-004833"},{"issue":"10","key":"5648_CR37","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/320169","volume":"32","author":"K Schmader","year":"2001","unstructured":"Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481\u20136.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"5648_CR38","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annepidem.2005.12.002","volume":"16","author":"W Opstelten","year":"2006","unstructured":"Opstelten W, Van Essen GA, Schellevis F, Verheij TJ, Moons KG. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol. 2006;16(9):692\u20135.","journal-title":"Ann Epidemiol"},{"issue":"1","key":"5648_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0950268803001523","volume":"132","author":"DM Fleming","year":"2004","unstructured":"Fleming DM, Cross KW, Cobb WA, Chapman RS. Gender difference in the incidence of shingles. Epidemiol Infect. 2004;132(1):1\u20135.","journal-title":"Epidemiol Infect"},{"key":"5648_CR40","doi-asserted-by":"publisher","unstructured":"Munoz-Quiles C, Lopez-Lacort M, Orrico-Sanchez A, Diez-Domingo J. Letter to the Editor regarding \"The role of age-sex interaction in the development of post-herpetic neuralgia\". Human vaccines Immunotherap. 2017;14(4):906-8. https:\/\/doi.org\/10.1080\/21645515.2017.1417715.","DOI":"10.1080\/21645515.2017.1417715"},{"key":"5648_CR41","doi-asserted-by":"publisher","unstructured":"Cebrian-Cuenca AM, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J, Herpes Zoster Res Grp V. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain. Bmc Infect Dis. 2011;11:302. https:\/\/doi.org\/10.1186\/1471-2334-11-302.","DOI":"10.1186\/1471-2334-11-302"},{"issue":"45","key":"5648_CR42","doi-asserted-by":"publisher","first-page":"6810","DOI":"10.1016\/j.vaccine.2018.08.080","volume":"36","author":"JL Meyers","year":"2018","unstructured":"Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018;36(45):6810\u20138.","journal-title":"Vaccine."},{"issue":"8","key":"5648_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/gerona\/glw189","volume":"72","author":"L Torcel-Pagnon","year":"2017","unstructured":"Torcel-Pagnon L, Bricout H, Bertrand I, Perinetti E, Franco E, Gabutti G, et al. Impact of underlying conditions on zoster-related pain and on quality of life following zoster. J Gerontol Series A-Biol Sci Med Sci. 2017;72(8):1091\u20137. https:\/\/doi.org\/10.1093\/gerona\/glw189.","journal-title":"J Gerontol Series A-Biol Sci Med Sci"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05648-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T19:03:39Z","timestamp":1607022219000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05648-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5648"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05648-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol, observational in design and using retrospective anonymized non-identifiable data transferred from the Valencia Ministry of Health to the research team according to the Spanish laws and institutional requirements, was approved by the Ethics Committee of Direcci\u00f3n General de Salud P\u00fablica \/ Centro Superior de Investigaci\u00f3n en Salud P\u00fablica (CEIC DGSP-CSISP). The Valencia Health System Data Commission [] granted permission for the transfer of specific anonymized data for the study development. Additionally, being that it is a retrospective study with 6\u2009years of study period (2009\u20132014), it would have been not possible to get individual informed consent from the whole population studied (more than 4 million inhabitants). Based on Helsinki\u2019s Declaration (principle 32) and the Law of Biomedical Reseach in Spain (Art. 58.2), the Ethics Committee accepted the exemption.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JDD and his institution received research grants from GSK and SPMSD related to HZ vaccine. He also acted as advisor for these vaccines to GSK and SPMSD. CMQ, AOS and MLL have attended to several congresses whose registration, travel and accommodation costs have been covered by GSK and SPMSD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"905"}}